Can I Participate?
If you’ve been diagnosed with epilepsy, you may be eligible to participate in the
X-TOLE2/X-TOLE3, or X-ACKT studies.
Eligibility criteria for those who have focal onset seizures (FOS) include:
Eligibility criteria for those who have primary generalized epilepsy include:
* If you are under 18 years old, your legal guardian must complete the questionnaire for you. PatientWing does not allow or accept questionnaires from anyone under the age of 18.
Other eligibility criteria apply.
What You May Receive
By enrolling in one of these epilepsy studies, you may receive:
Study medication at no cost
Study related medical care for epilepsy
Stipends for study visits
Reimbursements for travel accommodations
Your study doctor will provide more information about what you may receive if you choose to participate in this study after your initial conversation with him/her.
Why Should I Participate?
By joining this clinical study, you could contribute to advancements in medical knowledge and potentially help improve treatments and therapies for patients like yourself. Your participation can make a significant impact on epilepsy healthcare.
You will be seen by experts who have experience treating people with epilepsy, and your involvement in this study may lead to advancements in epilepsy research, understanding, and treatments.
Enrollment Participation Steps
Express Interest
Click here to see if you may qualify for one of the three studies.
Phone Call with PatientWing
If initially eligible, a PatientWing representative will call you to discuss the study, additional eligibility criteria, and answer your questions. If you are still eligible at the end of this screening call, you will be connected to a member of the team at a research site location for additional screening.
Screening at the Research Site
The team at a participating research site will determine if you are eligible to participate in the study.
Study
The study will last for about 7 months, broken down into three different time periods. The screening period will last up to 9.5 weeks, and the treatment period will last up to 12 weeks. Participants in the study will be required to keep an accurate seizure diary throughout the study. After the initial 12 weeks, there will be an opportunity for participants to receive the study medication for up to 3 years in an open label extension study, if you and the study team decide it is best.
Getting Started
To start your questionnaire, we need to know what type of seizures you have so we can determine which study would be the better option. Please note - each study is only looking for patients who have either focal onset seizures or primary generalized tonic-clonic seizures.
Please select what type of seizures you have:
Please answer the following question to proceed to our short questionnaire:
If you are unsure what type of seizures you have, you can still apply! Our team will contact you to discuss your medical history and if you pre-qualify, you’ll be connected with a research site to evaluate your eligibility for one of these studies.
What’s the Difference Between FOS & PGTCS?
These studies focus on two types of seizures: focal-onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS). Learn more about the differences between the two below:
Focal onset seizures (FOS)
Other names include partial seizures, complex partial seizures, focal seizure, focal epilepsy.
Focal onset seizures (FOS) start on one side of the brain and may or may not cause loss of awareness. They are the most common types of seizures in people with epilepsy.
Primary generalized tonic-clonic seizures (PGTCS)
Other names include generalized epilepsy, tonic-clonic seizures, idiopathic generalized epilepsy, epilepsy with generalized tonic-clonic seizures.
Primary generalized tonic-clonic seizures originate on both sides of the brain simultaneously and are characterized by loss of awareness and rhythmic whole body muscle contractions.
For Loved Ones
The family, friends, and healthcare teams of those with epilepsy play an important role in supporting their loved one's health and wellbeing.
If you are a loved one of someone with epilepsy, you can complete the questionnaire for the study on their behalf by clicking the button below. You have the option to either enter the patient's information or your own contact information. Please obtain approval from the patient prior to entering their information.
Frequently Asked Questions
Click “See if You May Qualify”, answer the question, and complete the questionnaire to express interest in the study.
The study is being conducted globally at different research sites. PatientWing will help you identify the best site for you to visit.
The study medication will be taken orally (by mouth) once daily. Participants may receive either the study medication (XEN1101) or a placebo during the study.
The study drug being tested is XEN1101.
The study medication, XEN1101, has been previously tested and is undergoing continuous testing for safety and efficacy.
Yes, there is a chance you will receive a placebo instead of the study medication, XEN1101. For the X-ACKT (PGTCS) study, there is a 50% chance of receiving the study medication and a 50% chance of receiving the placebo. For the X-TOLE2 and X-TOLE3 (FOS) studies, there is a 66% chance of receiving the study medication and a 33% chance of receiving the placebo. There will be an opportunity for participants who qualify to participate in the open-label extension (OLE) afterwards, where they will receive the study medication for up to 3 years if the participant and the study team decide it is best.
Research studies are designed in specific ways to test the study drug for safety and efficacy. An answer you provided was outside the guidelines for participating in this trial. This does not mean you may not qualify for other research studies.
You may have the opportunity to receive continued study medication during the Open Label Extension (OLE) if you are eligible. Your study doctor will be able to provide more information and answer any questions you may have during your Screening Visit. During the OLE, all enrolled patients will get XEN1101 and there is no placebo.
About Study Team
About The Sponsor
Xenon Pharmaceuticals is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. As the sponsor, Xenon is supporting these studies financially. The sponsor will not receive any potential participant personal data. To learn more, visit xenon-pharma.com.
About Us
Our mission to bring better treatments to more people faster starts with you. We help sponsors find patients to participate in their clinical studies. With our expertise in navigating the enrollment process, we're here for you every step of the way. To learn more, visit patientwing.com.
